Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Qingxiang Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1496-4180; OpenAlex author ID A5076659803. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 7

  1. Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. Co-author DOI 10.1158/1078-0432.ccr-25-1788↗
  2. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Co-author DOI 10.1016/j.drup.2024.101064↗
  3. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors … Co-author DOI 10.1111/bph.16289↗
  4. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. First author DOI 10.1158/1078-0432.ccr-23-0131↗
  5. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces… First author DOI 10.1021/acs.jproteome.3c00463↗
  6. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1016/j.mcpro.2022.100409↗
  7. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Co-author DOI 10.1124/jpet.120.000412↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert M. Straubinger · 6 shared papers, 2021–2024 · strength 1.19
  2. Jun Qu · 4 shared papers, 2022–2024 · strength 0.84
  3. Wen Wee Ma · 4 shared papers, 2021–2024 · strength 0.79
  4. Tista Roy Chaudhuri · 3 shared papers, 2024 · strength 0.64
  5. Sailee Suryakant Rasam · 2 shared papers, 2022–2023 · strength 0.39
  6. William J. Jusko · 2 shared papers, 2021–2022 · strength 0.32
  7. Jakob Michael Riedl · 1 shared paper, 2026 · strength 0.27
  8. Andrew Scott Liss · 1 shared paper, 2026 · strength 0.27
  9. Ryan Bruce Corcoran · 1 shared paper, 2026 · strength 0.27
  10. Jin Niu · 1 shared paper, 2024 · strength 0.22
  11. Michelle K. Greene · 1 shared paper, 2024 · strength 0.19
  12. Christopher J. Scott · 1 shared paper, 2024 · strength 0.19
  13. Martin M. Clynes · 1 shared paper, 2024 · strength 0.19
  14. Donald E. Mager · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.